Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn

Executive Summary

Allergan will pay a huge premium – up to $1.7bn in a milestone-heavy deal – for Tobira and $50m up front for the preclinical startup Akarna to expand its gastrointestinal franchise into the potentially lucrative NASH market.


Related Content

Intercept Increases Chance Of Success In NASH Without Significant Delay
Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?
Allergan’s RetroSense Buy Marks Move Into Gene Therapy
Allergan Sees Growth From New Launches, Not Big M&A
Tobira, Dong-A Stick To NASH Plans Despite CENTAUR Results
Tobira Says Secondary Endpoint In NASH Will Carry CVC Into Pivotal Study
Tobira/Dong-A Partnership Will Add DPP-4 Inhibitor For NASH Combo Therapy
Allergan's Back In The (M&A) Saddle Again Post Pfizer Breakup
Another Early-Stage VC Win: Pliant Raises $45m For Fibrosis Startup
Forest gaining 'relevant' GI position with Furiex buy


Related Companies